SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
AtheroGenics, Inc.{AGIX}-nasdaq
An SI Board Since September 2000
Posts SubjectMarks Bans Symbol
332 21 0 AGIX
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
282Nice to be hearing from you again, Mr. Clark. As you probably have observed, themlrb2113-7/1/2007
281<i>Thanks. The following is by way of background, for me and others. (keokalani'nui-7/1/2007
280<i> but is it possible, even at the ARISE dose, that liver tox is actuallyClarksterh-6/29/2007
279Yes, but is it possible, even at the ARISE dose, that liver tox is actually as rkeokalani'nui-6/29/2007
278<i>Mr. Clark: Dosages will be from 75 mg. to 300 mg. I would think they woClarksterh-6/29/2007
277ANDES: Mr. Clark: Dosages will be from 75 mg. to 300 mg. I would think they woulmlrb2113-6/28/2007
276Summary of CC after announcement of Diabetes Trial: a) The liver enzyme elevatiClarksterh-6/6/2007
275Motley Fool just put out a PR on Atherogenics and had the following to say: <Clarksterh-6/6/2007
274AtheroGenics Announces Business Plan to Focus on Advancing AGI-1067 in Diabetes sim1-5/31/2007
273AtheroGenics Cuts Half Its Work Force Friday May 25, 11:52 am ET AtheroGenics Cusim1-5/25/2007
272<i>These are results based on more patient exposure than needed for approvClarksterh-4/27/2007
271>>d) Strategy - indications to be pursued?<< Clark, AGIX provided sRudy Saucillo-4/27/2007
270I missed the CC but did any thing come up on the FOCUS effort that I understood Don Hurst-4/26/2007
269<i>>>> To be honest I am surprised they dropped it if for no othMENSO-4/26/2007
268Leo - <i> >>> ...if as you bolded "the study achieved a numbClarksterh-4/25/2007
267>>> ...if as you bolded "the study achieved a number of other impMENSO-4/25/2007
266OK Leo, if as you bolded "the study achieved a number of other important prDon Hurst-4/25/2007
265"While AGI-1067 did not show a difference from placebo in the composite priMENSO-4/25/2007
264AtheroGenics and AstraZeneca End Collaboration Agreement for AGI-1067 Monday Aprsim1-4/23/2007
263<but not the likely scenario.> I am less sure now given Antisoma's dekenhott-4/19/2007
262Exec VP bought 36,000 shares at $2.766. secform4.comidos-4/4/2007
261I am suggesting that their 250 and 319 patents won't hold on challenge. Of kenhott-4/2/2007
260rogerDewDiligence_on_SI-3/31/2007
259<i>How do you know the patent in question is not subject to a terminal disClarksterh-3/31/2007
258<i>Hmmm, not being clear I guess… Person A doesn't get a choice.</iDewDiligence_on_SI-3/31/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News